Nabriva Therapeutics Stock Forecast, Price & News

-0.08 (-5.16 %)
(As of 04/22/2021 12:00 AM ET)
Today's Range
Now: $1.47
50-Day Range
MA: $1.74
52-Week Range
Now: $1.47
Volume974,329 shs
Average Volume2.01 million shs
Market Capitalization$367.86 million
P/E RatioN/A
Dividend YieldN/A
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's lead product candidate is lefamulin, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia; for the treatment of acute bacterial skin and skin structure infection; and that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, osteomyelitis, and prosthetic joint infections. It is also developing CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.
Nabriva Therapeutics logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:NBRV
Phone(531) 649-2000
Year FoundedN/A



Sales & Book Value

Annual Sales$9.48 million
Book Value$0.44 per share


Net Income$-82,760,000.00
Net Margins-1,682.55%


Market Cap$367.86 million
Next Earnings Date5/10/2021 (Estimated)


Nabriva Therapeutics plc (NASDAQ:NBRV) Short Interest Update
April 1, 2021 |
Nabriva Therapeutics announces CFO retirement
February 3, 2021 |
NBRV Feb 2021 2.500 call
January 21, 2021 |
NBRV Jan 2021 5.000 put
January 4, 2021 |
Is NBRV A Good Stock To Buy Now?
December 11, 2020 |
See More Headlines


Overall MarketRank

1.32 out of 5 stars

Medical Sector

788th out of 2,024 stocks

Pharmaceutical Preparations Industry

375th out of 771 stocks

Analyst Opinion: 3.3Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
-0.08 (-5.16 %)
(As of 04/22/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NBRV News and Ratings via Email

Sign-up to receive the latest news and ratings for NBRV and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Nabriva Therapeutics (NASDAQ:NBRV) Frequently Asked Questions

Is Nabriva Therapeutics a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nabriva Therapeutics in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Nabriva Therapeutics stock.
View analyst ratings for Nabriva Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Nabriva Therapeutics?

Wall Street analysts have given Nabriva Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Nabriva Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Nabriva Therapeutics?

Nabriva Therapeutics saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 2,260,000 shares, an increase of 39.5% from the February 28th total of 1,620,000 shares. Based on an average daily trading volume, of 2,110,000 shares, the short-interest ratio is currently 1.1 days. Currently, 7.8% of the company's stock are sold short.
View Nabriva Therapeutics' Short Interest

When is Nabriva Therapeutics' next earnings date?

Nabriva Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, May 10th 2021.
View our earnings forecast for Nabriva Therapeutics

How were Nabriva Therapeutics' earnings last quarter?

Nabriva Therapeutics plc (NASDAQ:NBRV) posted its quarterly earnings data on Thursday, March, 11th. The biotechnology company reported ($1.11) earnings per share for the quarter, missing the consensus estimate of ($0.94) by $0.17. The biotechnology company had revenue of $2.46 million for the quarter, compared to analyst estimates of $0.61 million. Nabriva Therapeutics had a negative trailing twelve-month return on equity of 129.80% and a negative net margin of 1,682.55%.
View Nabriva Therapeutics' earnings history

How has Nabriva Therapeutics' stock been impacted by COVID-19?

Nabriva Therapeutics' stock was trading at $1.21 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, NBRV stock has increased by 21.5% and is now trading at $1.47.
View which stocks have been most impacted by COVID-19

What price target have analysts set for NBRV?

2 brokerages have issued 12 month price objectives for Nabriva Therapeutics' stock. Their forecasts range from $6.00 to $6.00. On average, they expect Nabriva Therapeutics' share price to reach $6.00 in the next twelve months. This suggests a possible upside of 308.2% from the stock's current price.
View analysts' price targets for Nabriva Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Nabriva Therapeutics' key executives?

Nabriva Therapeutics' management team includes the following people:
  • Mr. Theodore R. Schroeder, CEO & Director (Age 66, Pay $850.82k)
  • Dr. Steven P. Gelone, Pres & COO (Age 53, Pay $652.16k)
  • Dr. Colin Broom, Director (Age 65, Pay $40k)
  • Dr. Jennifer Schranz M.D., Chief Medical Officer (Age 56, Pay $733.81k)
  • Mr. Gary L. Sender, Chief Financial Officer (Age 59)
  • Mr. Robert L. Crotty, Gen. Counsel & Sec. (Age 47)
  • Mr. Francesco Maria Lavino, Chief Commercial Officer (Age 48)
  • Mr. Werner Heilmayer, VP of CMC & IP

Who are some of Nabriva Therapeutics' key competitors?

What other stocks do shareholders of Nabriva Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nabriva Therapeutics investors own include SCYNEXIS (SCYX), VBI Vaccines (VBIV), Agile Therapeutics (AGRX), Dynavax Technologies (DVAX), Acasti Pharma (ACST), Amarin (AMRN), AcelRx Pharmaceuticals (ACRX), Sorrento Therapeutics (SRNE), Vaxart (VXRT) and Heat Biologics (HTBX).

What is Nabriva Therapeutics' stock symbol?

Nabriva Therapeutics trades on the NASDAQ under the ticker symbol "NBRV."

How do I buy shares of Nabriva Therapeutics?

Shares of NBRV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nabriva Therapeutics' stock price today?

One share of NBRV stock can currently be purchased for approximately $1.47.

How much money does Nabriva Therapeutics make?

Nabriva Therapeutics has a market capitalization of $367.86 million and generates $9.48 million in revenue each year. The biotechnology company earns $-82,760,000.00 in net income (profit) each year or ($11.20) on an earnings per share basis.

How many employees does Nabriva Therapeutics have?

Nabriva Therapeutics employs 162 workers across the globe.

What is Nabriva Therapeutics' official website?

The official website for Nabriva Therapeutics is

Where are Nabriva Therapeutics' headquarters?

Nabriva Therapeutics is headquartered at 25-28 NORTH WALL QUAY IFSC, DUBLIN L2, 19406.

How can I contact Nabriva Therapeutics?

Nabriva Therapeutics' mailing address is 25-28 NORTH WALL QUAY IFSC, DUBLIN L2, 19406. The biotechnology company can be reached via phone at (531) 649-2000 or via email at [email protected]

This page was last updated on 4/23/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.